RDY vs VTRS

For growth investors, Dr.

Reddy's Laboratories Limited (RDY) is the stronger pick with 16. 6% revenue growth year-over-year, versus -3. 0% for Viatris Inc. (VTRS). Dr. Reddy's Laboratories Limited (RDY) offers the better valuation at 18. 8x trailing P/E (0. 2x forward), making it the more compelling value choice. Analysts rate Dr. Reddy's Laboratories Limited (RDY) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Dr.

Reddy's Laboratories Limited is actually cheaper at 0. 2x.

Over the past 5 years, Viatris Inc.

(VTRS) delivered a total return of +40. 3%, compared to -2. 3% for Dr. Reddy's Laboratories Limited (RDY). Over 10 years, the gap is even starker: RDY returned +66. 4% versus VTRS's -51. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Dr.

Reddy's Laboratories Limited (RDY) is the lower-risk stock at 0. 46β versus Viatris Inc. 's 0. 99β — meaning VTRS is approximately 118% more volatile than RDY relative to the S&P 500. On balance sheet safety, Dr. Reddy's Laboratories Limited (RDY) carries a lower debt/equity ratio of 14% versus 100% for Viatris Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Dr.

Reddy's Laboratories Limited (RDY) is pulling ahead at 16. 6% versus -3. 0% for Viatris Inc. (VTRS). On earnings-per-share growth, the picture is similar: Dr. Reddy's Laboratories Limited grew EPS 1. 5% year-over-year, compared to -466. 0% for Viatris Inc.. Over a 3-year CAGR, RDY leads at 14. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Dr.

Reddy's Laboratories Limited (RDY) is the more profitable company, earning 17. 4% net margin versus -24. 6% for Viatris Inc. — meaning it keeps 17. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RDY leads at 22. 1% versus -18. 6% for VTRS. At the gross margin level — before operating expenses — RDY leads at 58. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Dr.

Reddy's Laboratories Limited (RDY) trades at 0. 2x forward P/E versus 7. 1x for Viatris Inc. — 6. 9x cheaper on a one-year earnings basis.

All stocks in this comparison pay dividends.

Viatris Inc. (VTRS) offers the highest yield at 2. 8%, versus 0. 6% for Dr. Reddy's Laboratories Limited (RDY).

For long-horizon retirement investors, Dr.

Reddy's Laboratories Limited (RDY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 46), 0. 6% yield). Both have compounded well over 10 years (RDY: +66. 4%, VTRS: -51. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: RDY is a mid-cap high-growth stock; VTRS is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.